the purpose of this consultation is to select a service provider who will be responsible? perform the pharmacological evaluation and proof of therapeutic concept of p-ncs-bn-chelate conjugated to a commercial antibody targeting a type of cancer or its corresponding Fab fragment in gastric and/or colon cancers expressing Her2

the purpose of this consultation is to select a service provider who will be responsible? to perform the pharmacological evaluation and proof of therapeutic concept of p-ncs-bn-chelate conjugated to a commercial antibody targeting a type of cancer or its corresponding Fab fragment in gastric and/or colon cancers expressing Her2. This service will include several phases including: i) a phase of bioconjugation of p-ncs-bn-chelate to the antibody as well as its radiolabelling with 64cu; ii) an in vitro study phase on different tumor lines, performance of the complex in comparison with a complex combining a chelating type DOTA (p-ncs-bn-dota); iii) a phase of study of the biodistribution of the complex in priority on a gastric cancer model if the first steps were conclusive on this model; iv) a last phase will be devoted to the study of anti-tumor efficacy in priority on a gastric cancer model if the previous steps have been conclusive on this model